Izel Okcu

Izel Okcu

Auto-generated profile, based on publicly available information

Izel Okcu

Mayo Clinic Rochester, Rochester, MN

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2026 in Blood
Verified
Journal Article
Closed access
JAJuan Pablo Alderuccio
Juan Pablo Alderuccio
DBDiva Baggio
Diva Baggio
SHSunwoo Han
Sunwoo Han
PGPaola Ghione
Paola Ghione
INImran Nizamuddin
Imran Nizamuddin
KCKate Cwynarski
Kate Cwynarski
Secondary central nervous system (CNS) large B-cell lymphoma (SCNSL) occurs in the de novo setting, as a CNS-isolated relapse, or synchronous (concomitant CNS and systemic) relapse. SCNSL is a devastating event without therapeutic consensus. Thus, we aimed to evaluate treatment outcomes in an international cohort. Progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR, estimated using competing-risk models) were reported. Prognostic factors were identified in a 6-month landmark multivariate analysis. Outcomes after thiotepa autologous stem cell transplant (ASCT) and chimeric antigen receptor (CAR) T-cell therapy (CAR-T) delivered at relapse were compared after propensity score matching (PSM). A total of 1139 patients were included in the analysis (de novo: 537; relapsed SCNSL: 602). Two-year PFS estimates were 40.4%, 43.9%, and 16.2% for de novo SCNSL, CNS-isolated relapse, and synchronous relapse, respectively. Patients with CNS-isolated relapse demonstrated low rates of systemic recurrence (24-month CIR, 6%). Thiotepa-ASCT correlated with longer survival in de novo SCNSL (PFS: hazard ratio [HR], 0.57; P = .005; and OS: HR, 0.62; P = .023) and CNS-isolated relapses (PFS: HR, 0.55; P = .002; and OS: HR, 0.39; P< .0001). ASCT (thiotepa or no thiotepa) also associated with improved survival in synchronous relapses (PFS: HR, 0.57; P = .023; and OS: HR, 0.48; P = .019). Higher survival with thiotepa-ASCT than CAR-T was observed after PSM (PFS: HR, 0.45; P = .005 and OS: HR, 0.41; P = .014). These data support thiotepa-ASCT in eligible patients, particularly de novo disease and CNS-isolated relapses. CNS-isolated relapse was infrequently associated with systemic recurrence, supporting treatment regimens adopted from primary CNS lymphoma.

2 August 2024 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
IOIzel Okcu
Izel Okcu
YWYucai Wang
Yucai Wang
ABAllison M. Bock
Allison M. Bock
JZJihao Zhou
Jihao Zhou
MMMuhamad Alhaj Moustafa
Muhamad Alhaj Moustafa
GNGrzegorz S. Nowakowski
Grzegorz S. Nowakowski

7 March 2026 in Hematological Oncology
Verified
Journal Article
Open access
IOIzel Okcu
Izel Okcu
YWYucai Wang
Yucai Wang
ZLZhuo Li
Zhuo Li
LWLaunia J. White
Launia J. White
PJPatrick B. Johnston
Patrick B. Johnston
HTHan Tun
Han Tun
162 patients with relapsed secondary central nervous system lymphoma (R‐SCNSL) (median age, 65 years; male, 59.9%) including central nervous system (CNS)‐only ( n = 120) and concomitant CNS/systemic relapse ( n = 42) were retrospectively analyzed. Overall, 21.9% of patients were classified as high risk according to the CNS International Prognostic Index (CNS‐IPI). Several biological and clinical features were significantly associated with leptomeningeal involvement, including double‐ or triple‐hit (DHL/THL) status, MYC rearrangement, negative BCL6 expression by IHC, bone marrow involvement, and concomitant R‐SCNSL. Multivariable analysis showed that leptomeningeal involvement independently predicted inferior OS and was associated with a 98% increase in the hazard of death compared with parenchymal relapse (HR = 1.98, 95% CI: 1.20–3.26, p = 0.008). Based on anatomical localization, R‐SCNSL was classified into four subtypes: parenchymal‐only involvement (parenchymal‐CNS [P‐CNS], 68/42%) and parenchymal involvement plus systemic relapse (parenchymal‐concomitant [P‐concomitant], 17/10.5%); and leptomeningeal with or without parenchymal involvement (leptomeningeal‐CNS [LM‐CNS], 52/32.1%) and leptomeningeal with systemic relapse (leptomeningeal‐concomitant [LM‐concomitant], 25/15.4%). This anatomical classification significantly impacted OS and PFS ( p < 0.001). Two‐year OS and PFS were 58.2% and 29.1% for P‐CNS, 32.4% and 17.7% for P‐concomitant, 22% and 13.9% for LM‐CNS, and 7.1% and 0% for LM‐concomitant, respectively. ASCT showed a trend toward improved survival among patients with a response (CR/PR) in a 4‐month landmark analysis. These findings support the clinical application of the anatomical classification in the management of R‐SCNSL.

23 September 2026 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Verified
Journal Article
Open access
IOIzel Okcu
Izel Okcu
UDUrshila Durani
Urshila Durani
RLRobert J. Levy
Robert J. Levy
MMMuhamad Alhaj Moustafa
Muhamad Alhaj Moustafa
ARAllison C. Rosenthal
Allison C. Rosenthal
AKArushi Khurana
Arushi Khurana